35P - BCL2/p53 as significant prognostic indicator for ER-positive breast cancer

Date 04 May 2017
Event IMPAKT 2017
Session Welcome reception and Poster Walk
Topics Breast Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Yong Hwa Eom
Authors Y.H. Eom1, W.C. Park1, B.J. Chae1, B.J. Song2
  • 1Surgery, Seoul St. Mary’s Hospital, The Catholic University of Korea, 06591 - Seoul/KR
  • 2Surgery, Bucheon St.Mary's Hospital, The Catholic University of Korea, 14647 - Bucheon-si, Gyeonggi-do/KR



Background: B-Cell lymphoma/leukemia 2 (BCL2) and p53 involve in growth control and the apoptosis pathways, which appear to play a key role in tumor progression and prognosis. We analyzed the prognostic and predictive significance of BCL2 and p53 expression in estrogen receptor(ER)-positive breast cancer. Methods: We retrieved the data of 3,186 patients who were newly diagnosed with malignant breast cancer between August 2006 and December 2013. We analyzed BCL2/p53 index representing the relative expression of each protein and assessed its association with recurrence free survival(RFS), breast cancer-specific survival(BCSS), and overall survival(OS). Results A total of 511(60.2%) cases of ER-positive breast cancer showed BCL2-positive/p53-negative expression. 97 (11.4%) were BCL2-positive/p53-positive expression, 169(19.9%) were BCL2-negative/p53-negative expression, and 72(8.5%) were BCL2-negative/p53-positive expression. BCL2-positive/p53-negative expression showed an associated with favorable prognostic factors, such as well histological grade (p<0.001), no lymphovascular invasion (p=0.004), lower pathologic stage(p=0.033), progesterone receptor(PR)-positive (p<0.001), HER2 negative (p<0.001), lower Ki-67 level (<14%; p<0.001), and EGFR negative (p=0.001). BCL2/p53 expression showed a significant association with BCSS and OS in ER-positive breast cancer (p=0.002 and p=0.026, respectively). BCL2-positive/p53-negative and BCL2-positive/p53-positive breast cancer showed similar clinical prognostic course in recurrence and survival. In multivariate analysis, lymph node metastasis and BCL2-positive expression were independent prognostic factors for BCSS and OS. However, there was no correlation between BCL2/p53 expression and RFS. Conclusion: BCL2/p53 expression could be a predictor of BCSS and OS in ER-positive breast cancer.

Clinical trial identification